1. Home
  2. Stock quotes
  3. Институт стволовых клеток человека
  4. Financial Statements
  5. Income Statement
Институт стволовых клеток человека logo
Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Income Statement 2007-2026 | ISKJ

Annual Income Statement Институт стволовых клеток человека

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Revenue

 1.37 B 1.14 B 1.18 B 1.08 B 836 M 645 M 494 M 390 M 311 M 359 M 420 M 317 M 262 M 193 M 146 M 96.8 M 65.5 M

Cost Of Revenue

 402 M 260 M 290 M 310 M 164 M 79.5 M 92.4 M 67.2 M 47.4 M 29.5 M 16.5 M 32.9 M 28.6 M 2.41 M 4.91 M 1.95 M 415 K

Gross Profit

 966 M 877 M 891 M 774 M 671 M 565 M 402 M 323 M 263 M 330 M 403 M 284 M 233 M 190 M 142 M 94.8 M 65.1 M

Gross Profit Ratio

 0.71 0.77 0.75 0.71 0.8 0.88 0.81 0.83 0.85 0.92 0.96 0.9 0.89 0.99 0.97 0.98 0.99

General and Administrative Expenses

 64.1 M 31.9 M 31.5 M 25.8 M 41.3 M 25.9 M 22.4 M 65.6 M 35.1 M 46.7 M 19.9 M 10.3 M 7.77 M 10.1 M 8.97 M 9.43 M 8.3 M

Selling And Marketing Expenses

 166 M 72.5 M 61.9 M 43.9 M 38.9 M 29.9 M 46.1 M 52.6 M 63.3 M 27.2 M 22.7 M 29.9 M 15.6 M 16.3 M 7.28 M 7.66 M 11.3 M

Selling General And Administrative Expenses

 603 M 104 M 93.3 M 69.7 M 80.2 M 55.8 M 68.5 M 118 M 98.4 M 73.9 M 42.5 M 40.2 M 23.4 M 26.4 M 16.3 M 17.1 M 19.6 M

Other Expenses

 58.1 M 582 M 691 M 557 M 400 M 53.4 M 4.65 M 29.9 M 5.44 M 59.7 M 3.31 M 1.06 M -905 K 144 M 95.6 M 71.3 M 37.3 M

Operating Expenses

 691 M 766 M 795 M 629 M 507 M 515 M 459 M 460 M 358 M 381 M 361 M 314 M 216 M 177 M 114 M 88.6 M 57.3 M

Cost And Expenses

 1.09 B 1.03 B 1.08 B 939 M 672 M 595 M 552 M 527 M 406 M 411 M 378 M 314 M 245 M 180 M 119 M 90.6 M 57.7 M

Interest Expense

 - 67.8 M 50.7 M 40.2 M 41.5 M 30.2 M 30.8 M 27.1 M 8.65 M 11.9 M 18.5 M 5.45 M 414 K 302 K 356 K 215 K 40 K

Depreciation And Amortization

 49.2 M 53.5 M 81.3 M 74.9 M 28.7 M 29.7 M 40.5 M 24 M 26.2 M 25 M 22.5 M 8.99 M 6.07 M 4.99 M 3.56 M 2.22 M 814 K

EBITDA

 326 M 151 M 161 M 209 M 203 M 128 M -2.71 M -98.6 M -58.9 M 37.1 M 64.3 M 10.8 M 25.7 M 15.8 M 53.7 M 11 M 8.89 M

EBITDA Ratio

 0.24 0.13 0.15 0.2 0.25 0.2 -0.01 -0.21 -0.19 0.1 0.15 0.03 0.11 0.11 0.37 0.11 0.14

Operating Income

 276 M 111 M 92.4 M 147 M 181 M 117 M -58.1 M -144 M -95.5 M -51.3 M 42.7 M -11.8 M 16.6 M 7.1 M 27.4 M 6.21 M 7.34 M

Operating Income Ratio

 0.2 0.1 0.08 0.14 0.22 0.18 -0.12 -0.37 -0.31 -0.14 0.1 -0.04 0.06 0.04 0.19 0.06 0.11

Income Before Tax

 211 M 29.3 M 29.5 M 93.5 M 101 M -53.8 M -127 M -150 M -60.3 M 160 K 27.4 M -142 M 19.2 M 9.47 M 50.1 M 8.57 M 8.04 M

Income Before Tax Ratio

 0.15 0.03 0.02 0.09 0.12 -0.08 -0.26 -0.38 -0.19 0.0 0.07 -0.45 0.07 0.05 0.34 0.09 0.12

Income Tax Expense

 16.7 M 6.23 M -4.09 M -9.93 M -9.89 M -35.6 M -17.2 M -18.7 M 2.22 M 16.8 M 10.7 M 7.67 M -1.71 M 3.05 M 5.8 M 1.92 M 2.05 M

Net Income Ratio

 0.12 0.04 0.03 0.1 0.1 -0.05 -0.21 -0.29 -0.17 -0.04 0.04 -0.47 0.07 0.03 0.3 0.07 0.09

Earnings Per Share, EPS

 1.82 0.53 0.42 1.38 1.13 -0.46 -1.37 -1.48 -0.69 -0.18 0.2 -2 2.86 0.12 0.89 0.11 0.1

EPS Diluted

 1.82 0.53 0.42 1.38 1.13 -0.46 -1.37 -1.48 -0.69 -0.18 0.2 -2 2.86 0.12 0.89 0.11 0.1

Weighted Average Shares Outstanding

 92.8 M 86.9 M 80 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 71.5 M 60 M 60.1 M 61.3 M 61.6 M

All numbers in RUB currency

Quarterly Income Statement Институт стволовых клеток человека

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q1

Revenue

 373 M 373 M 374 M 374 M 311 M 311 M 309 M 309 M 260 M 260 M 624 B 312 M 557 B 278 M 557 B 315 M 631 B 227 M 453 B 225 M 192 M 192 M 176 M 176 M 147 M 147 M 142 M 125 M 112 B 115 B 105 M 82.6 M 109 M 93.6 M 79.4 B 79.4 B 76 M 76 M 92.6 B 92.6 B 87.1 M 106 M 102 M 102 M 121 M

Cost Of Revenue

 93.1 M 93.1 M 119 M 119 M 82.1 M 82.1 M 132 M 132 M 96.5 M 96.5 M 439 B 120 M 404 B 111 M 404 B 161 M 477 B 33.1 M 256 B 62.3 M 39.2 M 39.2 M 26.1 M 26.1 M 35.7 M 35.7 M 39.9 M 12.6 M 31 M 39.8 M 19.8 M 22.2 M 42.9 M 12.7 M 36.5 M 36.5 M 23.7 M 23.7 M 25.2 M 25.2 M 17.8 M 70.6 M 13.5 M 13.5 M 42.6 M

Gross Profit

 280 M 280 M 255 M 255 M 228 M 228 M 176 M 176 M 163 M 163 M 185 B 192 M 153 B 168 M 153 B 154 M 154 B 193 M 197 B 163 M 153 M 153 M 150 M 150 M 111 M 111 M 102 M 113 M 112 B 115 B 85.3 M 60.4 M 66.1 M 81 M 79.4 B 79.4 B 52.3 M 52.3 M 92.6 B 92.6 B 69.3 M 35 M 88.6 M 88.6 M 78 M

Gross Profit Ratio

 0.75 0.75 0.681 0.681 0.736 0.736 0.572 0.572 0.629 0.629 0.296 0.616 0.274 0.602 0.274 0.489 0.244 0.854 0.435 0.724 0.797 0.797 0.852 0.852 0.756 0.756 0.719 0.899 1.0 1.0 0.811 0.731 0.606 0.865 1.0 1.0 0.688 0.688 1.0 1.0 0.796 0.331 0.868 0.868 0.647

General and Administrative Expenses

 17.4 M 17.4 M 20.1 M 20.1 M 12 M 12 M 11 M 11 M 8.66 M 8.66 M - 11.6 M - 7.37 M - 12.6 M - 6.53 M - 16.7 M 9.55 M 9.55 M 9.66 M 9.66 M 6.63 M 6.63 M 3.34 M 2.72 M 10.6 M 10.1 M 9.3 M 19.6 M 15.4 M 20 M 11.3 M 11.3 M 9.38 M 9.38 M 15.8 M 15.8 M 9.72 M 24.3 M 6.53 M 6.53 M 20.9 M

Selling And Marketing Expenses

 52.7 M 52.7 M 39.2 M 39.2 M 43.4 M 43.4 M 34.4 M 34.4 M 22.6 M 22.6 M - 32.6 M - 19.8 M - 24.4 M - 15.6 M - 18 M 11.1 M 11.1 M 5 M 5 M 16.6 M 16.6 M 20.1 M 11.6 M 18.3 M 6.14 M 8.33 M 16.2 M 21.5 M 8.81 M 23.6 M 23.6 M 11.8 M 11.8 M 12 M 12 M 4.33 M 7.47 M 10.7 M 10.7 M 5.7 M

Selling General And Administrative Expenses

 177 M 177 M 149 M 149 M 156 M 156 M 135 M 135 M 117 M 117 M 121 B 134 M 111 B 115 M 111 B 107 M 163 B 98.3 M 101 B 90.1 M 98.5 M 98.5 M 81.5 M 81.5 M 93.8 M 93.8 M 23.4 M 14.3 M 92.4 M 95.6 M 17.6 M 35.8 M 36.9 M 28.8 M 70.2 M 70.2 M 51.1 M 51.1 M 73.2 M 73.2 M 66 M 31.7 M 76.5 M 76.5 M 26.6 M

Other Expenses

 18.8 M 18.8 M 8.67 M 8.67 M 17 M 17 M -19.5 M -19.5 M 11.6 M 11.6 M -278 B 30.4 M -220 B 19 M -212 B 15.5 M -270 B 26.5 M -201 B 15.1 M 18.3 M 18.3 M -6.02 M -6.02 M 17.3 M 17.3 M -5.91 M 6.85 M 5.19 M 10.5 M 28.3 M 4.3 M 5.43 M -8.11 M 3.68 M 3.68 M 2.63 M 2.63 M -3.6 M -3.6 M 8.14 M 70 M 9.91 M 9.91 M -20.6 M

Operating Expenses

 196 M 196 M 169 M 169 M 176 M 176 M 153 M 153 M 132 M 132 M -157 B 165 M -109 B 135 M -101 B 124 M -107 B 125 M -101 B 109 M 117 M 117 M 89.4 M 89.4 M 112 M 112 M 115 M 101 M 100 M 112 M 120 M 138 M 112 M 89.8 M 81.6 M 81.6 M 61.5 M 61.5 M 85.9 M 85.9 M 76.4 M 31.7 M 88.4 M 88.4 M 26.6 M

Cost And Expenses

 289 M 289 M 288 M 288 M 258 M 258 M 285 M 285 M 228 M 228 M 439 B 285 M 404 B 246 M 404 B 285 M 477 B 158 M 256 B 171 M 156 M 156 M 116 M 116 M 148 M 148 M 155 M 114 M 131 M 152 M 140 M 160 M 138 M 89.8 M 118 M 118 M 85.2 M 85.2 M 111 M 111 M 94.2 M 102 M 102 M 102 M 69.2 M

Interest Expense

 - - - - - - - - - - 35.6 B - 28.1 B - 28.1 B - 34 B - 16.2 B - - - - - - - 8.39 M 8.05 M - - 16.7 M 2.84 M 3.9 M 3.64 M - - - - - - - 3.79 M - - 4.49 M

Depreciation And Amortization

 12.8 M 12.8 M 7.96 M 7.96 M 17.1 M 17.1 M 6.89 M 6.89 M 13.1 M 13.1 M 44.5 B 16.2 M 36.8 B 13 M -8.28 B 13.9 M -11.1 B 12.6 M -19.8 B 10.5 M 11.1 M 11.1 M 2.23 M 2.23 M 12.3 M 12.3 M 20.8 M 9.2 M 782 K 9.27 M 5.18 M 7.82 M 4.44 M 6.55 M 6.39 M 6.39 M 5.57 M 5.57 M 5.23 M 5.23 M 6.16 M 71.1 M 6.35 M 6.35 M -19.4 M

EBITDA

 96 M 96 M 96.1 M 96.1 M 67.3 M 67.3 M 33.1 M 33.1 M 40.3 M 40.3 M 72.2 B 48.5 M 80.3 B 45.9 M 43.5 B 44.3 M 36.2 B 81.2 M 76.9 B 64.3 M 47.6 M 47.6 M 62.5 M 62.5 M 10.7 M 10.7 M -55.4 M 32.7 M -18.3 M -27.4 M 3.4 M -49.6 M -58.8 M -4.64 M -32.2 M -32.2 M -3.61 M -3.61 M -11.5 M -11.5 M -961 K 74.4 M 8.46 M 8.46 M 32 M

EBITDA Ratio

 0.258 0.258 0.257 0.257 0.217 0.217 0.107 0.107 0.155 0.155 0.116 0.156 0.144 0.165 0.078 0.14 0.057 0.358 0.17 0.285 0.247 0.247 0.355 0.355 0.073 0.073 0.021 0.232 -0.0 -0.0 0.006 -0.623 -0.54 -0.049 -0.0 -0.0 -0.048 -0.048 -0.0 -0.0 -0.011 0.704 0.083 0.083 0.265

Operating Income

 83.2 M 83.2 M 85.4 M 85.4 M 52.4 M 52.4 M 23.7 M 23.7 M 31.8 M 31.8 M 27.7 B 26.7 M 43.5 B 32.9 M 51.8 B 30.4 M 47.3 B 68.6 M 96.7 B 53.8 M 36.4 M 36.4 M 60.2 M 60.2 M -1.55 M -1.55 M -6.1 M 3.71 M -19.1 M -36.7 M -38.9 M -62.3 M -46.3 M 3.88 M -38.6 M -38.6 M -9.18 M -9.18 M -18.5 M -18.5 M -7.12 M 3.3 M 156 K 156 K 51.4 M

Operating Income Ratio

 0.223 0.223 0.228 0.228 0.169 0.169 0.077 0.077 0.122 0.122 0.044 0.086 0.078 0.118 0.093 0.096 0.075 0.303 0.213 0.239 0.189 0.189 0.343 0.343 -0.011 -0.011 -0.043 0.03 -0.0 -0.0 -0.37 -0.755 -0.425 0.041 -0.0 -0.0 -0.121 -0.121 -0.0 -0.0 -0.082 0.031 0.002 0.002 0.426

Income Before Tax

 50.7 M 50.7 M 84 M 84 M 21.7 M 21.7 M -61 K -61 K 14.7 M 14.7 M 11 B 3.95 M 23.7 B 10.8 M 23.7 B 6.46 M 13.3 B 40.3 M 80.5 B 18.8 M 31.9 M 31.9 M -40.6 M -40.6 M 13.7 M 13.7 M -84.6 M 15.5 M -28.9 M -29.2 M -18.5 M -60.2 M -62.7 M -8.27 M -39 M -39 M 8.82 M 8.82 M -20.8 M -20.8 M 20.9 M 70.6 M -11.7 M -11.7 M 27.5 M

Income Before Tax Ratio

 0.136 0.136 0.225 0.225 0.07 0.07 -0.0 -0.0 0.057 0.057 0.018 0.013 0.043 0.039 0.043 0.02 0.021 0.178 0.178 0.083 0.166 0.166 -0.231 -0.231 0.093 0.093 -0.595 0.124 -0.0 -0.0 -0.176 -0.73 -0.575 -0.088 -0.0 -0.0 0.116 0.116 -0.0 -0.0 0.24 0.668 -0.115 -0.115 0.228

Income Tax Expense

 1.14 M 1.14 M 4.68 M 4.68 M 3.68 M 3.68 M 3.36 M 3.36 M 249 K 249 K 200 M 100 K -4.29 B 2.14 B -4.29 B 898 K 1.8 B 5.86 B -11.7 B 5.47 B 528 K 528 K 14.6 M 14.6 M 3.21 B 3.21 B -5.65 M -9.68 M 2.16 M 282 K -6.26 M -11.9 M 403 K -1 M 778 K 778 K 1.89 M 1.89 M 2.49 M 2.49 M 5.89 M 16.6 M 2.04 M 2.04 M 6.4 M

Net Income Ratio

 0.112 0.112 0.183 0.183 0.051 0.051 0.034 0.034 0.048 0.048 0.017 -0.013 0.05 0.035 0.05 0.001 0.018 0.16 0.204 0.074 0.133 0.133 -0.192 -0.192 0.113 0.113 -0.585 0.198 -0.0 -0.0 -0.06 -0.506 -0.514 -0.078 -0.0 -0.0 0.108 0.108 -0.0 -0.0 0.192 0.511 -0.128 -0.128 0.175

Earnings Per Share, EPS

 0.001 0.001 0.001 0.001 0.0 0.0 0.0 0.0 0.0 0.0 0.15 - 0.38 0.0 0.38 - 0.16 0.001 1.23 K 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -1.11 0.33 -0.0 -0.0 -0.084 -0.56 -0.75 -0.097 -0.001 -0.001 0.0 0.0 -0.0 -0.0 0.0 0.72 -0.0 -0.0 0.28

EPS Diluted

 0.001 0.001 0.001 0.001 0.0 0.0 0.0 0.0 0.0 0.0 0.15 - 0.38 0.0 0.38 - 0.16 0.001 1.23 K 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -1.11 0.33 -0.0 -0.0 -0.084 -0.56 -0.75 -0.097 -0.001 -0.001 0.0 0.0 -0.0 -0.0 0.0 0.72 -0.0 -0.0 0.28

Weighted Average Shares Outstanding

 73.9 B 73.9 B 75.3 B 75.3 B 74.2 B 74.2 B 88.8 B 88.8 B 86.3 B 86.3 B 73.4 B 85 B 72.8 B 75.8 B 72.8 B 75 B 72.8 B 75 B 75 M 75 B 75.5 B 75.5 B 75 B 75 B 75 B 75 B 75 M 75 M 75 B 75 B 75 M 75 M - 75 M 75 B 75 B 75 B 75 B 75 B 75 B 75 B 75 M 75 B 75 B 75 M

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Институт стволовых клеток человека (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
 		- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
 		- 1052.0 % $ 415 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
 		$ 14.21 -0.42 % $ 208 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
 		- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
 		- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
 		- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
 		- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
 		- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
 		$ 3.35 -2.62 % $ 295 M usaUSA
Biophytis SA Biophytis SA
BPTS
 		- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
 		$ 216.26 -0.83 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
 		- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
 		- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
 		$ 19.12 -0.57 % $ 894 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
 		$ 0.62 2.14 % $ 7.1 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
 		- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
 		- -24.86 % $ 820 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
 		$ 46.45 -0.91 % $ 4.18 B schweizSchweiz
Acasti Pharma Acasti Pharma
ACST
 		- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
 		- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
 		- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
 		- -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
 		- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
 		$ 1.4 -0.36 % $ 357 M britainBritain
Exelixis Exelixis
EXEL
 		$ 41.13 -0.69 % $ 11.2 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
 		- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
 		- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
 		$ 2.63 - $ 16.5 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
 		$ 6.64 -3.63 % $ 421 K usaUSA
Atreca Atreca
BCEL
 		- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
 		- -4.8 % $ 255 M usaUSA
Genmab A/S Genmab A/S
GMAB
 		$ 25.59 -0.35 % $ 16.5 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
 		$ 7.64 -0.72 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
 		- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
 		- 0.49 % $ 251 B cayman-islandsCayman-islands
Halozyme Therapeutics Halozyme Therapeutics
HALO
 		$ 61.68 -1.88 % $ 7.39 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
 		$ 26.99 -2.21 % $ 1.55 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
 		- -74.18 % $ 955 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
 		$ 6.43 0.31 % $ 52.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
 		- - $ 3.67 B usaUSA
Immatics N.V. Immatics N.V.
IMTX
 		$ 9.32 -2.0 % $ 586 M germanyGermany
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
 		$ 69.48 -1.85 % $ 11.1 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
 		$ 1.33 -2.92 % $ 235 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
 		$ 4.29 -2.94 % $ 822 M canadaCanada
Akouos Akouos
AKUS
 		- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		- 1.93 % $ 17.4 M usaUSA